Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Shares of Novo Nordisk A/S (NVO) climbed 0.4% on Monday and rose in extended trading after the Danish drugmaker said it had ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.